1	
2	
3	
4	The cost-effectiveness of mammography-based female breast
5	cancer screening in Canadian populations: a systematic review
6	
7	
8	Talha Tahir ¹ , Melanie Mitsui Wong ² , Rabia Tahir ² , Michael Mitsui Wong ³
9	
10	¹ Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
11	² Bachelor of Health Sciences (Honours), McMaster University, Hamilton, Ontario, Canada.
12	³ Bachelor of Life Sciences (Honours), McMaster University, Hamilton, Ontario, Canada.
13	
14	
15	* Corresponding Author
16	Email: <u>talha.tahir@medportal.ca</u> (TT)
17	
18	
19	[¶] These authors contributed equally to this work.
20	
21	

^{1, 2, 3} Address: McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4L8

22 Abstract

23 Introduction

24 Mammography-based breast cancer screening is an important aspect of female breast 25 cancer prevention within the Canadian healthcare system. The current literature on female breast 26 cancer screening is largely focused on the health outcomes that result from screening. There is 27 comparatively little data on the cost-effectiveness of the screening. Therefore, this paper sought 28 to conduct a systematic review of the literature on the cost effectiveness of mammography-based 29 breast cancer screening within female Canadian populations. 30 31 **Materials and methods** 32 A systematic review was performed in the PubMed database to identify all studies 33 published within the last 10 years that addressed breast cancer screening and evaluate cost-34 effectiveness in a Canadian population. 35 **Results** 36 37 The search yielded five studies for inclusion, only three of which were applicable to 38 average-risk Canadian women. The benefits of mortality reduction rose approximately linearly 39 with costs, while costs were linearly dependent on the number of lifetime screens per woman. 40 Moreover, triennial screening for average-risk women aged 50-69 years was found to be the 41 most cost-effective in terms of cost per quality adjusted life year. The use of MRI in conjunction 42 with mammography for women with the BRCA 1/2 mutation was found to be cost-effective 43 while annual mammography-based screening for women with dense breasts was found to be 44 cost-ineffective.

45

46 Conclusion

In spite of the growing interest to enhance breast cancer screening programs, analyses of the cost-effectiveness of mammography-based screening within Canadian populations are scarcely reported and have heterogeneous methodologies. The existing data suggests that Canada's current breast cancer screening policy to screen average-risk women aged 50-74, biennially or triennially is cost-effective. These findings could be of interest to health policy makers when making decisions regarding resource allocation; however, further studies in this field are required in order to make stronger recommendations regarding cost-effectiveness.

54

55 Introduction

56 Mammography-based female breast cancer screening is a modern staple of preventive 57 healthcare [1]. It is administered in primary care facilities across Canada and the cost of the 58 intervention is covered under Canada's public healthcare system [1]. While there is no direct 59 policy associated with screening for breast cancer, the government of Canada makes 60 recommendations to primary care physicians and the general public about screening protocols 61 [1]. It is currently recommended that women between the ages of 50-74 years who are at 62 average-risk of developing breast cancer are screened via mammography biennially or triennially 63 [1]. There are established benefits to breast cancer screening, particularly because of its high 64 prevalence and stage variable mortality [2]. In Canada, breast cancer represents 25% of all 65 cancer diagnoses among women and 13% of all cancer diagnoses overall [2]. However, as a 66 result of the implementation of screening practices and improved therapeutic interventions, the

67	mortality rate for female breast cancer has decreased by 44% since its peak in 1986 [2]. Since
68	2010, more than 80% of all female breast cancer diagnoses have occurred at stage I and II, with
69	only 5% being diagnosed at stage IV [2]. However, the statistics on mortality rates and disease
70	incidence only tell the story of breast cancer from an epidemiological perspective. To truly
71	understand how to create effective policy for organized breast cancer screening across Canada, it
72	is necessary to investigate the cost-effectiveness of current screening protocols.

73

74 Breast cancer screening recommendations are officially developed by the Canadian Task 75 Force on Preventive Health Care (CTFPHC) [1]. The most recent breast cancer screening 76 guidelines were released by the CTFPHC in 2018 [1]. While these guidelines and embedded 77 recommendations incorporate a variety of factors, the emphasis is generally placed on patient 78 costs and benefits. There is comparatively little exposure given to the financial costs of screening 79 and false-positive scenarios. There is no analysis of cost-effectiveness within the current 2018 80 Canadian breast cancer screening guidelines and there is only a cursory discussion of the 81 economic implications of screening within the older 2011 guidelines. Moreover, the two articles 82 that were cited for cost-effectiveness in the 2011 CTFPHC guidelines were studies conducted in 83 South Korea and the United States [3]. To make informed policy decisions about breast cancer 84 screening, it is imperative to analyze Canadian data on cost-effectiveness [1,3]. Therefore, this 85 systematic review intends to evaluate the cost-effectiveness of female breast cancer screening policies in Canadian populations through an analysis of current literature. The objective of this 86 87 paper is to declare Canada's current breast cancer screening policies as either cost-effective or 88 ineffective and make recommendations that will increase cost-effectiveness in the future.

90 Materials and methods

91	A systematic literature review for all original studies that addressed breast cancer
92	screening and/or those that attempted to evaluate cost-effectiveness was conducted in accordance
93	with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
94	Statement guidelines for reporting [4,5] (S1 Table. Criteria for literature search methods and
95	inclusion criteria were determined a priori. No review protocol exists for this study. A systematic
96	search was performed within the PubMed electronic database for articles published in peer-
97	reviewed journals, with a full text available in English. Only papers published within the last 10
98	years were included to ensure the review was relevant to current breast cancer screening
99	practices and treatment methods within Canada. In collaboration with an information specialist,
100	we developed a search strategy tailored to the PubMed database using search terms such as "cost
101	effectiveness", "cost-benefit analysis", "cost evaluation", "Canada", "screening",
102	"mammography", "cancer", "neoplasm", "sarcoma", and "breast" to identify studies
103	investigating cost-effectiveness of mammogram screening in Canadian female populations (see
104	S2 Table for the full search strategy).

105

106 Eligibility Criteria


107 Title and abstract screening were conducted in duplicate by TT and MMW to identify 108 studies for full-text review. The search was limited to studies that featured data on the cost-109 effectiveness of mammography-based female breast cancer screening policies within a Canadian 110 demographic. Only English full-text, original research articles published within the past 10 years 111 were eligible for inclusion. Any discrepancies raised during the screening process were resolved 112 through consensus by TT and MMW. Full texts of selected publications were retrieved and

113	assessed for eligibility by TT and MMW. Following full-text review, papers which contained
114	original research related to breast cancer screening policies in Canada were included. Reference
115	lists of included papers were also assessed to collect additional records and ensure that all
116	relevant studies were captured.
117	
118	Data Extraction
119	Should the publication have met all eligibility criteria, the study characteristics,
120	parameters of the model used, incremental cost-effectiveness ratios, average total cost of
121	screening, incremental cost per death averted, and number of women screened to avert one death,
122	were independently extracted by TT and MMW. If eligible studies did not report data necessary
123	for inclusion in the systematic review, efforts were made to contact the corresponding authors
124	directly.
125	
126	Risk of Bias & Quality Assessment
127	Risk of bias and study quality was assessed independently by TT and MMW using the
128	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Checklist (S3 Table)
129	[6]. This 24-item evaluation tool includes guidelines for critically appraising the quality of
130	reporting economic model characteristics, analytic methods, study parameters, incremental costs
131	and outcomes, amongst others [6]. For each item, evidence of its description within each study
132	was reported. Final risk of bias evaluations were determined through consensus and review of
133	source documents.

135 **Results**

- 136This search identified a total of 248 citations. After title and abstract screening, 29
- 137 articles were selected to undergo full text review. This initial round of screening did not apply
- the recency requirement of 10 years mentioned previously. Upon applying this recency
- 139 requirement during the examination of full text articles, 5 papers were accepted and included in
- 140 the systematic review (Fig 1). The characteristics of included articles are presented in Table 1.
- 141 Please refer to S4 Table in the supplementary repository to view the articles excluded by full text
- 142 screening and their reasons for exclusion.

143 Fig 1. *PRISMA* diagram of literature review process for PubMed Search and Screening.



145 Table 1. Characteristics and findings of included studies.

Study Authors	Year	Findings	
Pataky et al. [7]	2013	Annual mammography plus MRI screening resulted in an ICER of \$50,900/QALY compared to annual mammogram screening alone.	
Pataky et al. [8]	2014	Annual screening resulted in an additional 0.0014 QALYs compared to screening once every 2 years.	
Gocgun et al. [9]	2015	Screening women aged 50-69 years once every 5 years is the most optimal with regards to cost per life saved. Annual mammogram screening is not cost-effective.	
Mittmann et al. [10]	2015	Screening women aged 50-69 once every three years is the most cost-effective at \$83,070 per life year gained and \$94,762 per QALY.	
Mittmann et al. [11]	2018	Annual screening per 1000 women costs the healthcare system \$7.4-10.7 million compared to a no-screening scenario, which would cost the system \$3.0 million per 1000 women. All screening programs increased life years gained and QALYs.	

146

147 The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 148 Checklist was applied to the 5 studies included in this review [6]. Upon evaluation, every article 149 fulfilled most of the criteria on the checklist (S1 Table) and thus were deemed to be of good 150 quality. All studies clearly presented well-defined research questions, characterized the study 151 population, and provided justifications for the specific type of analytical model used. A notable 152 difference between the articles was the presence of confidence intervals. The 2015 and 2018 153 papers by Mittman et al. did not contain confidence intervals or any other metric expressing 154 uncertainty about their point estimates [10,11]. However, given that the papers incorporated a 155 variety of cost, sensitivity, and incidence data to generate their models, this may explain the omission of confidence intervals within these studies. 156

157	This review takes a qualitative approach at evaluating the included studies. A meta-
158	analysis could not be conducted due to the significant heterogeneity between the studies. In
159	addition, the use of different models with varying input parameters, discounting rates, time
160	horizons, and costs made it infeasible to statistically combine the studies.
161	The included studies varied in the populations studied, which were subdivided into two
162	categories: those presenting a cost-effectiveness analysis for screening women at an average-risk

- 163 for breast cancer, and those assessing cost-effectiveness for high-risk women. Three articles
- 164 calculated the cost-effectiveness for screening average-risk women, Mittman et al 2015, Mittman
- 165 et al 2018, and Gocgun et al 2015 (Table 2) [9–11].

Table 2. Characteristics of studies assessing cost-effectiveness for screening average-risk women

167	women.	

Study Authors (year)	Primary Outcome	Screening Intervention	Time Horizon	Costs
Gocgun et al. (2015) [9]	Incremental cost per death averted	Film-based mammography	20 years	2015 Canadian dollars using Ontario-based costs for screening and treatment
Mittmann et al. (2015) [10]	Incremental cost per QALY	Digital mammography	Lifetime	2012 Canadian dollars using Ontario-based costs for screening and treatment
Mittmann et al. (2018) [11]	Incremental cost per QALY	Digital mammography	Lifetime	2012 Canadian dollars using Ontario-based costs for screening and treatment

169	Both papers by Mittman et al. used the same University of Wisconsin Breast Cancer
170	Epidemiology Simulation model. but addressed the topic from different perspectives [10,11].
171	The 2018 Mittman et al. paper considered cost-effectiveness from a single payer public
172	healthcare system perspective, [11] whereas the 2015 paper by the same lead author considered
173	cost-effectiveness from a societal perspective [10]. Both studies also used digital mammography
174	as the screening intervention, expressed their costs in 2012 Canadian dollars using Ontario-based
175	costs (Ontario Health Insurance Plan (OHIP)) for screening and treatment, and employed a
176	lifetime horizon for cost calculation. The homogenous methodologies applied across these two
177	papers thus made their respective estimates easy to compare.
178	The two Mittman papers concluded that the benefits of mortality reduction rose
179	approximately linearly with costs, while costs were linearly dependent on the number of lifetime
180	screens per woman. Then, the decision to screen is largely based on willingness to pay. To
181	compare cost-effectiveness, an analysis of the incremental cost-effectiveness ratios (ICERs) of
182	the two Mittman et al. studies was performed (Table 3).

Table 3. Cost-effectiveness of screening scenarios in Mittman et al. 2015 and Mittman et al. 2018. [10,11]

	Triennial 50-69 years	Biennial 50-69 years	Annual 50-69 years
Mittman et al. 2015 [10]	\$94,762/QALY	\$97,006/QALY	\$159,858/QALY
Mittman et al. 2018 [11]	\$36,918/QALY	\$38,142/QALY	\$65,944/QALY

The 2015 Mittman et al. study had far higher ICERs due to its inclusion of costs to society, particularly loss in productivity [10]. Only 3 screening scenarios are examined in Table 2, as the 50-69 years age group closely approximates the current Canadian recommendation to screen average-risk women between 50-74 years of age. In both studies, the simulations with the 50-74 years age group were weakly dominated by the 50-69 years age group. Therefore, these studies provide support to the argument that average-risk women aged 70-74 years should not be screened using digital mammography.

193 The third study that examined cost-effectiveness for average-risk women was conducted 194 by Gocgun et al. [9]. This study cannot be directly compared against the Mittman et al. studies 195 because it did not calculate incremental cost per quality adjusted life year (QALY), instead 196 opting to calculate incremental cost per death averted. Moreover, unlike the two Mittman et al. 197 studies, Gocgun et al. did not use a lifetime horizon; instead, costs were evaluated over a horizon 198 of 20 years. Gocgun et al. used data from the Canadian National Breast Cancer Screening Study 199 to create and validate their model [9]. It should be noted that the data used to create this model 200 was generated using film-based mammography, a screening technique that has since been 201 replaced with digital mammography. The increased sensitivity of digital mammography may 202 have resulted in more cost-effective outcomes. Ontario (OHIP) data expressed in 2015 Canadian 203 dollars was used to input costs of screening and treatment scenarios [9].

Gocgun et al. (2015) concluded that more aggressive screening scenarios generate greater health benefits but at an increased cost (Table 4) [9]. Screening average-risk women aged 50-69 years every 5 years was found to have the lowest incremental costs, but the highest number of women screened to avert one death. Biennial screening for average-risk women between 50-69

208 years had the most favorable combination of incremental cost per death averted and number of

- 209 women screened to avert one death. Similar to Mittman et al., Gocgun et al. found a sharp
- 210 increase in cost per utility, or in this case, cost per death averted when comparing biennial or
- triennial screening to annual screening [9].

212 Table 4. Cost-effectiveness of select screening scenarios from Gocgun et al. 2015. [9]

	Triennial 50-69 years	Biennial 50-69 years	Annual 50-69 years
Average total cost (screening, diagnosis and treatment costs)	\$16,298,486	\$18,414,393	\$24,091,226
Incremental cost per death averted	\$626,973	\$654,940	\$981,265
Number of women screened to avert one death	1,332	960	785

213

214 The remaining 2013 and 2014 studies by Pataky et al. included in this review focused on 215 populations at high-risk for breast cancer (Table 5) [7,8]. Both studies constructed their 216 Markovian model based on breast cancer incidence, treatment, and screening costs in British 217 Columbia using a lifetime horizon for the calculation of costs. The 2013 study by Pataky et al. 218 examined cost-effectiveness of using Magnetic Resonance Imaging (MRI) in conjunction with 219 mammography for women carrying the BRCA1/2 mutation, expressing costs in 2008 Canadian 220 dollars [7]. Women with the BRCA1/2 mutation are at a higher risk of developing breast cancer, 221 therefore, they may benefit from the higher sensitivity of the MRI [12]. Pataky et al. (2013)

found an ICER of \$50,911/QALY for using MRI in conjunction with mammography instead of
using mammography alone [7]. At a willingness to pay of \$100,000/QALY, the use of MRI
screening is cost-effective 85.6% of the time. However, Pataky et al. found the model to be
highly dependent on the cost of an MRI scan, which may change the applicability of the result in
locations where an MRI scan is more expensive [7].

227 The 2014 study by Pataky et al. investigated the cost-effectiveness of annual vs. biennial 228 mammography screening for women with dense breasts, expressing costs in 2007 Canadian 229 dollars [8]. The sensitivity of mammography screening was significantly lower in women with 230 dense breasts, consequently making them more likely to be diagnosed with interval cancers [13]. 231 The study found that screening breast cancer in women with dense breasts annually instead of 232 biennially has an ICER of \$565,912/QALY [8]. The extremely high ICER coupled with the fact 233 that only 43.4% of the simulations showed annual screening to reduce QALYs relative to 234 biennial screening suggest the cost-ineffectiveness of this strategy [8]. Moreover, the sensitivity 235 data used in this study was for film-based mammography instead of digital mammography, 236 making it difficult to judge cost-effectiveness in a healthcare environment dominated by digital 237 mammography. Based on this study, annual breast cancer screening for women with dense 238 breasts can effectively be considered cost-ineffective until further research proves otherwise [8].

Table 2. Characteristics of studies assessing cost-effectiveness for screening high-risk women

Study Authors (year)	Primary Outcome	Screening Intervention	Time Horizon	Costs
Pataky et al. (2013) [7]	Incremental cost per QALY	Magnetic resonance imaging in conjunction with mammography	Lifetime	2008 Canadian dollars using British Columbia-based costs for screening and treatment
Pataky et al. (2014) [8]	Incremental cost per QALY	Film-based mammography	Lifetime	2007 Canadian dollars using British Columbia-based costs for screening and treatment

242

243 **Discussion**

To the best of our knowledge, this is the first systematic review that assesses the cost 244 245 effectiveness of mammography-based breast cancer screening within Canadian female 246 populations. The results of the 5 studies included in this review ultimately suggest that 247 aggressive screening strategies incur higher costs, but they also provide more health benefits. 248 The optimal strategy for any given situation is decided largely by willingness to pay. However, a 249 public healthcare system like Canada must make concrete decisions on which screening practices 250 to implement based on clinical and cost-effectiveness. To make such a decision, it is necessary to 251 understand the thresholds for cost-effectiveness within the field of oncology. 252 According to a 2010 paper that evaluated the attitudes of US and Canadian physicians on

253 cost-effectiveness, the majority of oncologists in both Canada and the United States see

254 \$100,000/life-year as the threshold for cost-effective oncology treatments [14]. Traditionally,

when examining healthcare interventions, the threshold of \$50,000/QALY (USD) has been cited [15]. However, in recent literature, the trend has been to use a threshold of \$100,000/QALY with the World Health Organization and many economists arguing that thresholds of anywhere from \$110,000 to \$160,000 per QALY should be used in a population like the United States, given median household income and other factors [15]. If one were to extrapolate these results to Canada, it seems that at the very minimum a value of \$100,000/QALY should be used when evaluating the cost-effectiveness of breast cancer screening procedures.

262 Having made this assumption, we find that the estimates given by both the 2018 and 2015 263 Mittman et al. studies for biennial and triennial screening of average-risk women between the 264 ages of 50-69 years fall below the threshold of \$100,000/QALY [10,11]. It seems that even with 265 the inclusion of societal costs such as loss in productivity, biennial and triennial screening of 266 women aged 50-69 years is cost-effective. The results of the study by Gocgun et al. cannot be 267 analyzed by the metric of cost-effectiveness we have used above, as the study did not integrate 268 OALYs in its incremental cost-effectiveness ratios. Moreover, Gocgun et al.'s study, more than 269 any other in this review, suffered from a poorly constructed model that was forced to make 270 multiple simplifying assumptions due to data scarcity. For example, due to data scarcity, Gocgun 271 et al. assumed the stage distribution of clinically presenting cancer for the 60-69 age group to be 272 the same as that for the 50-59 age groups [9]. As a result, we will exclude Gocgun et al. results in 273 making a decision about the cost-effectiveness of Canada's current breast cancer screening 274 policies.

The 2014 study by Pataky et al. on the cost-effectiveness of annual vs. biennial
mammography breast cancer screening for women with dense breasts found an ICER of

277	\$565,912/QALY [8]. The high ICER and the variation seen in the simulations for annual versus
278	biennial breast cancer screening for women with dense breasts leaves us uncertain about its cost-
279	effectiveness. Lastly, the 2013 Pataky et al. study looking at using MRI screening in conjunction
280	with mammography on women carrying the BRCA1/2 mutation found an ICER of
281	\$50,911/QALY as compared to mammography screening alone [7]. This is well below our cost-
282	effectiveness threshold of \$100,000/QALY and suggests that using MRI in conjunction with
283	mammography is indeed cost- effective for that specific population of women.
284	The consensus seems to be that the current breast cancer screening policies of Canada, to
285	screen average-risk women aged 50-74 years biennially or triennially, are cost-effective.
286	However, the results of the above studies suggest that it is cost-ineffective to screen women with
287	dense breasts annually and that it is cost-effective for women with the BRCA1/2 mutation to be
288	given the option of using MRI in conjunction with digital mammography.
289	The results of the review must be tempered by the heterogeneity and limitations of the
290	constitutive studies. The included papers used different models that were validated with different
291	reference data, utilized different time horizons, and conducted different numbers of simulations.
292	Moreover, the cost-effectiveness of breast cancer screening programs tends to be highly sensitive
293	to the discounting rate, as many of the costs are accrued near the beginning of the program while
294	the benefits are reaped near the end. Every study used a different discounting rate with 1.5% as
295	the lowest and 5% as the highest. The methodological differences between studies mean that the
296	results of this review must be interpreted with caution and that it is difficult to make firm
297	statements about the cost-effectiveness of breast cancer screening in Canada.

299	Despite the heavy focus on optimizing breast cancer screening protocols, there is a
300	scarcity of literature available on the cost-effectiveness of breast cancer screening within
301	Canadian populations. Further studies are required to be able to make stronger recommendations
302	regarding cost-effectiveness, which will prove critical in making decisions regarding resource
303	allocation. The concerns presented in this review could serve as a basis for consideration by
304	health policy makers, who must consider cost as a major factor when evaluating mammogram
305	screening programs.
306	

308 **References**

- 309 1. Klarenbach S, Sims-Jones N, Lewin G, Singh H, Thériault G, Tonelli M, et al.
- 310 Recommendations on screening for breast cancer in women aged 40-74 years who are not
- at increased risk for breast cancer. CMAJ. 2018;190: E1441–E1451.
- doi:10.1503/cmaj.180463
- Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer
 Statistics 2018. Can Cancer Soc. 2018. doi:0835-2976
- 315 3. The Canadian Task Force on Preventative Health Care. Recommendations on screening
- for breast cancer in average-risk women aged 40-74 years. CMAJ. 2011;183: 1991–2001.
- doi:10.1503/cmaj.110334
- 318 4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The
- 319 PRISMA statement for reporting systematic reviews and meta-analyses of studies that
- 320 evaluate health care interventions: explanation and elaboration. J Clin Epidemiol.
- 321 2009;62: e1–e34. doi:10.1016/j.jclinepi.2009.06.006
- 322 5. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred
- 323 reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS
- 324 Medicine. 2009. doi:10.1371/journal.pmed.1000097
- 325 6. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.
- 326 Consolidated health economic evaluation reporting standards (CHEERS)-explanation and
- 327 elaboration: A report of the ISPOR health economic evaluation publication guidelines
- 328 good reporting practices task force. Value Heal. 2013;346: f1049.
- doi:10.1016/j.jval.2013.02.002
- 330 7. Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, et al. Cost-

- 331 effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. BMC
- 332 Cancer. 2013;13: 339. doi:10.1186/1471-2407-13-339
- 333 8. Pataky R, Ismail Z, Coldman AJ, Elwood M, Gelmon K, Hedden L, et al. Cost-
- effectiveness of annual versus biennial screening mammography for women with high
- mammographic breast density. J Med Screen. 2014;21: 180–188.
- doi:10.1177/0969141314549758
- 337 9. Gocgun Y, Banjevic D, Taghipour S, Montgomery N, Harvey BJ, Jardine AKS, et al.
- 338 Cost-effectiveness of breast cancer screening policies using simulation. Breast. 2015;24:
- 339 440–448. doi:10.1016/j.breast.2015.03.012
- 340 10. Mittmann N, Stout NK, Lee P, Tosteson ANA, Trentham-Dietz A, Alagoz O, et al. Total
- 341 cost-effectiveness of mammography screening strategies. Heal Reports. 2015;26: 16–25.
- doi:10.1001/jama.274.11.881
- 343 11. Mittmann N, Stout NK, Tosteson ANA, Trentham-Dietz A, Alagoz O, Yaffe MJ. Cost-
- 344 effectiveness of mammography from a publicly funded health care system perspective. C
- 345 Open. 2018;6: E77-86. doi:10.9778/cmajo.20170106
- 12. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et
- al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2
- 348 mutation carriers. JAMA J Am Med Assoc. 2017;317: 2402–2416.
- doi:10.1001/jama.2017.7112
- 350 13. Harvey JA, Bovbjerg VE. Quantitative Assessment of Mammographic Breast Density:
- 351 Relationship with Breast Cancer Risk. Radiology. 2004;230: 29–41.
- 352 doi:10.1148/radiol.2301020870
- 353 14. Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental divide?

- 354 The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health
- 355 policies associated with new cancer drugs. J Clin Oncol. 2010;28: 4149–4153.
- 356 doi:10.1200/JCO.2010.29.1625
- 357 15. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness The curious
- resilience of the \$50,000-per-QALY threshold. N Engl J Med. 2014;371: 796–797.
- doi:10.1056/NEJMp1405158
- 360

361 Supporting information

- 362 S1 Table. PRISMA Checklist.
- 363 S2 Table. Search strategy.
- 364 S3 Table. CHEERS Checklist for Included Articles.
- 365 S4 Table. Papers excluded from full text review along with reasons for exclusion.